BMI View: The Netherlands has a well establish pharmaceutical and healthcare sector. In 2016, the
pharmaceutical market will face yet another year of contraction in value terms before returning to growth
in 2017. Medicine sales will be driven by an ageing population a ..."
BMI View: The value of the Dutch pharmaceutical market will see yet another year of contraction in 2016,
although we expect a return to growth - albeit marginal - in the following years. A relatively low risk
environment and a well establish healthcare sector, thanks ..."
BMI View: The Netherlands has a well-developed healthcare system due to generous public expenditure
over the years. Despite newly introduced cost-cutting measures, government spending on healthcare will
continue to increase in local currency terms, especially as the w ..."
BMI View: The healthcare market in the Netherlands will continue to offer considerable commercial
opportunities. As a part of the Health Insurance Act, implemented in 2006, private insurance for curative
care and supplemental benefits is mandatory for the entire popul ..."
BMI View: Although the Dutch economy is expected to grow above the eurozone average over 2015 and
2016, the government will most likely continue to target the healthcare sector, resulting in further drug
price cuts as it responds to rising healthcare costs from the de ..."
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - The Netherlands". The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement lan ..."
BMI View: The contraction of the Dutch economy during the first quarter of 2014 casts doubt on the
durability of its recovery. The government will continue with austerity measures to meet the terms of EU
budget criteria and further restrictions on drug expenditure loo ..."
BMI View: Despite Netherlands' expectations for a return to positive economic growth in 2014, its
government will continue with austerity measures to comply with EU budget criteria. Drugmakers have
generally charged what the market will bear in both developed and emer ..."
BMI View: We anticipate further restrictions to medicine prices in 2014 under the Medicines Prices Act,
which will subdue the outlook for both patented and generic drugmakers in the country. This comes despite
expectations for a return to positive economic growth in 2 ..."
BMI View: As a result of the high and increasing average age in the Netherlands, our outlook for
healthcare expenditure in the country is broadly positive. On the other hand, we maintain that the
pharmaceutical sector in the Netherlands will not see a return to positi ..."